Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

127 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study aims to compare long-acting darbepoetin alpha versus short-acting epoetin alpha erythropoietin-stimulating agents in Egyptian hemodialysis patients. The main questions aim to answer are:

* What are the effectiveness and safety of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients?
* What is the cost-effectiveness of long- acting versus short-acting erythropoietin-stimulating agents in Egyptian hemodialysis patients?

Participants will be divided into 2 groups; epoetin alfa (short-acting ESA), Eprex group, and darbepoetin alfa (long-acting ESA), Aranesp group for six month study period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Pentoxifylline on Anemia in Hemodialysis Patients

NCT05708248

Hemodialysis Complication

UNKNOWN NA

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

NCT06983756

Erythropoietin Resistant Anemia (EPO Resistant Anemia)

NOT_YET_RECRUITING

Comparison Among Erythropoietin Stimulating Agents

NCT02049346

Anemia of End Stage Renal Disease

COMPLETED PHASE4

Study of Rule-Based Algorithms in Anemia Management in Prevalent Hemodialysis Patients and Its Relation to Patients' Outcomes

NCT06996717

Anemia in End Stage Renal Disease

ACTIVE_NOT_RECRUITING PHASE1

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

NCT00563446

Anemia Kidney Failure, Chronic Peritoneal Dialysis, Continuous Ambulatory

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anemia, the most prevalent and dangerous complication of chronic kidney disease, is caused when the kidney is unable to produce enough erythropoietin to promote the creation of red blood cells (CKD). Anemia from CKD is linked to higher mortality, cardiovascular disease, exhaustion, dyspnea, and a lower quality of life for patients.

It has been demonstrated that using erythropoietin-stimulating drugs (ESAs) in treating renal anemia increases survival, lowers cardiovascular morbidity, and improves the quality of life.

Epoetin alfa (EPO), an ESA with a shorter half-life, and darbepoetin alfa (DPO), are the two ESAs used in hemodialysis centers the most frequently in Egypt (longer half life ) Epoetin alfa is dosed one to three times per week, whereas darbepoetin alfa is dosed once per week or every two weeks.

Compared to epoetins, darbepoetin alfa's extended dose interval may benefit patients and their medical professionals.

Despite the fact that ESAs save CKD patients from needing blood transfusions, clinical trials, meta-analyses, and mortality hazards with ESAs targeting high hemoglobin levels have been shown. A higher ESA dose may be linked to cardiovascular problems and all-cause mortality independent of hemoglobin level.

Darbepoetin alfa has a lower risk of side effects because it only requires 35% of the dosage of epoetin alfa to attain the same target hemoglobin level. Darbepoetin alfa also has an advantage over epoetin alfa in that it makes it easier for the body to mobilize iron into the bone marrow to cause successful erythropoiesis, which may shield the body from any potential negative effects from having too much iron stored there. Despite this, the medication that Egyptian hemodialysis centers use the most is (EPO). This study compares (DPO) and (EPO) to determine which should be utilized based on efficacy, safety, and cost.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia of Chronic Kidney Disease Chronic Renal Failure Chronic Renal Failure Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aranesp group

Aranesp group: patients received darbepoetin alpha prefilled syringe subcutaneously once weekly or biweekly

No interventions assigned to this group

Eprex group

Eprex group: patients received epoetin alpha prefilled syringe subcutaneously one to three times per week

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have been stable and undergoing hemodialysis three times per week for at least three months
* Age must be 18 or older
* Patients who had been receiving a single form of ESA treatment for at least three months before the study's launch.

Exclusion Criteria

* altered the type of ESA therapy; 2) underwent significant surgery; or (3) received RBC transfusions
* failed to adhere to dialysis therapy, as shown by missing more than two appointments each month.
* have COVID-19 infection.
* had cancer.
* underwent a kidney transplant
* were pregnant or nursing mothers
* were not followed up for the full six-month research period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No